v3.25.2
Revenue - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2023
Feb. 28, 2019
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2025
Jun. 30, 2024
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement     $ 58,879,000 $ 43,190,000   $ 111,322,000 $ 85,063,000
Immune Medicine Service Revenue              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement     3,900,000 1,800,000   7,500,000 6,400,000
Medicare Reimbursements              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement     2,100,000 $ 1,500,000   4,100,000 $ 2,800,000
MRD Development Agreements | Maximum              
Disaggregation Of Revenue [Line Items]              
Additional milestone payment receivable     406,500,000     406,500,000  
Genentech Collaboration Agreement              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement         $ 7,700,000    
Non-refundable upfront payments received   $ 300,000,000       300,000,000  
Additional transaction price of regulatory milestone payment $ 10,000,000            
Expected revenue through milestone payments     1,800,000,000     $ 1,800,000,000  
Genentech Collaboration Agreement | Regulatory Milestones              
Disaggregation Of Revenue [Line Items]              
Additional transaction price of regulatory milestone payment $ 10,000,000            
Genentech Collaboration Agreement | Maximum              
Disaggregation Of Revenue [Line Items]              
Revenue recognition expected period           10 years  
Genentech Collaboration Agreement | Maximum | Regulatory Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     65,000,000     $ 65,000,000  
Genentech Collaboration Agreement | Maximum | Development Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     300,000,000     300,000,000  
Genentech Collaboration Agreement | Maximum | Commercial Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     $ 1,430,000,000     $ 1,430,000,000  
Genentech Collaboration Agreement | Minimum              
Disaggregation Of Revenue [Line Items]              
Revenue recognition expected period           9 years